Previous 10 | Next 10 |
2024-04-16 07:00:03 ET Kaveri Pohlman from BTIG issued a price target of $38.00 for XNCR on 2024-04-16 05:16:00. The adjusted price target was set to $38.00. At the time of the announcement, XNCR was trading at $20.11. The overall price target consensus is at $56.00 with...
2024-04-09 08:17:05 ET More on Xencor Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript Xencor: Standing Out With XmAb Technology Xencor slips as Piper cuts citing patient death in cancer study Read the full article on Seeking Alpha For further det...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 2...
2024-03-16 19:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-- Clinical development focus on high-potential XmAb ® T cell engagers and selective dual checkpoint inhibitor, vudalimab -- -- Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced bey...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-24 17:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tu...
2024-02-05 17:52:08 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Agilent, Incyte to collaborate on companion diagnostics development Why did Incyte stock go up today? Positive drug study Seeking Alpha ...
2024-02-03 06:57:03 ET Summary Xencor demonstrates strong YoY revenue growth through achieved milestones with major industry partners. The strategic sale of royalty interests strengthens Xencor's balance sheet and provides flexibility for future strategic moves. Xencor's pipel...
News, Short Squeeze, Breakout and More Instantly...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-25 06:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...